New drug cocktail shows promise for rare sarcomas
NCT ID NCT04172805
First seen Jun 17, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This phase 2 trial tested a combination of two drugs—anlotinib and toripalimab—in 70 people with advanced soft-tissue sarcoma that had stopped responding to standard treatment. The goal was to see if the combo could shrink tumors or slow the disease. The study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Xing Zhang
Guangzhou, Guangdong, 510060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
anlotinib and toripalimab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced soft-tissue sarcoma who have run out of standard therapies.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. Side effects from the drug combination could be serious.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.